Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)

ConclusionThe objective response rate and median survival time in Japanese patients treated with nivolumab were lower in daily practice than the>30% and  >30  months, respectively, seen in global phase III trials. The occurrence of immune-related adverse events may be a predictor for survival and response to treatment with nivolumab.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research